Anteris Technologies Global (NASDAQ:AVR) Stock Rating Reaffirmed as “Overweight” by Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a research report issued on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 139.62% from the stock’s current price.

A number of other equities research analysts also recently weighed in on AVR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a research note on Wednesday, October 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Stock Down 2.9%

AVR traded down $0.19 during trading on Wednesday, reaching $6.26. 1,739,979 shares of the company’s stock were exchanged, compared to its average volume of 1,124,172. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06. The business has a 50 day moving average price of $8.32 and a 200 day moving average price of $8.05. The company has a market capitalization of $610.10 million, a P/E ratio of -3.21 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The business had revenue of $1.01 million for the quarter, compared to analyst estimates of $1.50 million. During the same quarter in the prior year, the firm earned ($0.58) EPS. As a group, research analysts forecast that Anteris Technologies Global will post -1.21 EPS for the current year.

Insider Activity

In related news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the business’s stock in a transaction on Monday, October 5th. The stock was bought at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the completion of the acquisition, the insider owned 12,778,380 shares in the company, valued at $95,965,633.80. The trade was a 5.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 1,554,730 shares of company stock worth $11,694,513 and sold 3,008,459 shares worth $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new position in shares of Anteris Technologies Global during the second quarter valued at $78,000. Abel Hall LLC bought a new position in shares of Anteris Technologies Global in the first quarter valued at about $63,000. Bartlett & CO. Wealth Management LLC raised its holdings in shares of Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after buying an additional 8,200 shares during the last quarter. One68 Global Capital LLC bought a new position in shares of Anteris Technologies Global in the second quarter valued at about $128,000. Finally, J. Derek Lewis & Associates Inc. bought a new position in shares of Anteris Technologies Global in the fourth quarter valued at about $70,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.